Catalyst Wire Dossier Catalyst Wire Dossier

Trastuzumab deruxtecan

trastuzumab deruxtecan · Daiichi Sankyo
Drug timelines are a Plus or Pro feature.

40 regulatory and trial events tracked for Trastuzumab deruxtecan, covering 2023-06-15 to 2026-06-09. Get the full timeline:

Most recent: Clinical Trial Update: Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer [Phase 3]

See pricing